RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company's President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the ROTH 22nd Annual OC Growth Stock Conference on Wednesday, March 17, 2010 at 10:00 a.m. PT. This annual three-day conference will be held March 15-17 at the Ritz Carlton Laguna Niguel in Dana Point, CA.
A live webcast of the presentation will be available on the "Investors" section of the Company's website, www.rxipharma.com. A replay of the presentation will be available for 30 days.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi compounds and delivery methods. RXi uses its own version of RNAi compounds -- rxRNA™ -- that provide an advanced alternative to conventional small interfering RNAs (siRNAs) and define the next generation of RNAi technology. rxRNA™ compounds are designed specifically for therapeutic use and contain many of the properties required to progress RNAi based drugs into the clinic. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong early intellectual property position in RNAi chemistry and delivery. www.rxipharma.com
Contacts:
RXi Pharmaceuticals
Gregg Beloff, 508-929-3604
ir@rxipharma.com
or
Investors
S.
A. Noonan Communications
Susan Noonan, 212-966-3650
susan@sanoonan.com
or
Media
Rx
Communications Group
Eric Goldman, 917-322-2563
egoldman@rxir.com
